Oral capsules of tetra‐hydro‐cannabinol ( THC ), cannabidiol ( CBD ) and their combination in peripheral neuropathic pain treatment
European Journal of Pain · 2023-04 · 27 (4) · 492-506
DOI: 10.1002/ejp.2072 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Pain, online erschienen am 12.01.2023. Verfasst von Kanita Zubcevic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Cannabidiol, Neuralgia. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministeriet Sundhed Forebyggelse.
Abstract (Originalsprache)
Background
Cannabinoids are often prescribed for neuropathic pain, but the evidence‐based recommendation is ‘weak against’.
Objectives
The aim was to examine the effect of two cannabinoids and their combination in peripheral neuropathic pain.
Methods
This was a randomized, double‐blind, trial with treatment arms for cannabidiol (CBD), tetra‐hydro‐cannabinol (THC), CBD and THC combination (CBD/THC), and placebo in a 1:1:1:1 ratio and flexible drug doses (CBD 5–50 mg, THC 2.5–25 mg, and CBD/THC 5 mg/2.5 mg–50 mg/25 mg). Treatment periods of 8‐week duration were proceeded by 1 week for baseline observations. Patients with painful polyneuropathy, post‐herpetic neuralgia and peripheral nerve injury (traumatic or surgical) failing at least one previous evidence‐based pharmacological treatment were eligible for inclusion. The primary outcome was the change in weekly average of daily pain measured with a numeric rating scale (NRS). Trail Making Test (TMT) was used as one of the tests of mental functioning.
Results
In all, 145 patients were included in the study of which 118 were randomized and 115 included in the intention‐to‐treat analysis. None of the treatments reduced pain compared to placebo ( p = 0.04–0.60). Effect sizes as estimated in week 8 (positive values worse and negative better than placebo) were CBD mean 1.14 NRS points (95% CI 0.11–2.19), THC 0.38 (CI −0.65 to 1.4) and CBD/THC −0.12 (−1.13 to 0.89).
Conclusions
CBD, THC and their combination did not relieve peripheral neuropathic pain in patients failing at least one previous evidence‐based treatment for neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Multidisciplinary Pain Center, National Hospital, Copenhagen, Denmark.
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Søren H Sindrup
Förderung
- Ministeriet Sundhed Forebyggelse
Zitieren
APA
Zubcevic, K., Petersen, M., Bach, F. W., Heinesen, A., Enggaard, T. P., Almdal, T. P., Holbech, J. V., Vase, L., Jensen, T. S., Hansen, C. S., Finnerup, N. B., & Sindrup, S. H. (2023). Oral capsules of tetra‐hydro‐cannabinol ( THC ), cannabidiol ( CBD ) and their combination in peripheral neuropathic pain treatment. European Journal of Pain, 27(4), 492-506. https://doi.org/10.1002/ejp.2072
Vancouver
Zubcevic K, Petersen M, Bach FW, Heinesen A, Enggaard TP, Almdal TP, et al. Oral capsules of tetra‐hydro‐cannabinol ( THC ), cannabidiol ( CBD ) and their combination in peripheral neuropathic pain treatment. European Journal of Pain. 2023;27(4):492-506. doi:10.1002/ejp.2072
BibTeX
@article{Zubcevic2023,
author = {Zubcevic, Kanita and Petersen, Merete and Bach, Flemming Winther and Heinesen, Aksel and Enggaard, Thomas Peter and Almdal, Thomas Peter and Holbech, Jakob Vormstrup and Vase, Lene and Jensen, Troels Stahelin and Hansen, Christian Stevns and Finnerup, Nanna Brix and Sindrup, Søren H},
title = {Oral capsules of tetra‐hydro‐cannabinol ( THC ), cannabidiol ( CBD ) and their combination in peripheral neuropathic pain treatment},
journal = {European Journal of Pain},
year = {2023},
volume = {27},
number = {4},
pages = {492--506},
doi = {10.1002/ejp.2072}
}
EUVIMED